Abstract: Methods of treating patients having susceptible viral infections, especially chronic hepatitis C infection by administering to said patient a therapeutically effective amount of a combination therapy of interferon-alfa and ribavirin for a time sufficient to lower HCV-RNA in association with a therapeutically effective amount of an antioxidant for a time sufficient to ameliorate ribavirin-related hemolysis are disclosed.

Abstract: There is disclosed a method for treating antiviral treatment naives patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving a combination therapy using (1) a therapeutically effective inducing amount of ribavirin and a therapeutically effective induction dosing amount of pegylated interferon-alfa, e.g, pegylated interferon-alfa-2b for a first treatment time period sufficient to substantially lower detectable HCV-RNA, followed by (2) administering a therapeutically effective amount of ribavirin and an therapeutically effective amount of pegylated interferon-alfa, e.g., pegylated interferon alfa-2b for a second treatment time period sufficient to eradicate detectable HCV-RNA at least by end of the second treatment time period and to maintain no detectable HCV-RNA for at least 24 weeks after the end of the second treatment time period.

Abstract: Methods for treating treatment-naive as well as treatment-experienced adult and pediatric patients having HIV-1 infections as well as patients co-infected with HIV-1 and HCV involving administering a therapeutically effective amount of pegylated interferon-alfa, e.g., pegylated interferon alfa-2b as monotherapy or preferably in association with a therapeutically effective amount of at least one of ribavirin, IL-2, IL-12, pentafuside alone or in combination with a therapeutically effective amount of an anti-HIV-1 drug therapy, e.g., HAART are disclosed.

Abstract: There is disclosed a method for treating antiviral treatment naives patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving a combination therapy using (1) a therapeutically effective inducing amount of ribavirin and a therapeutically effective induction dosing amount of pegylated interferon-alfa, e.g, pegylated interferon-alfa-2b for a first treatment time period sufficient to substantially lower detectable HCV-RNA, followed by (2) administering a therapeutically effective amount of ribavirin and an therapeutically effective amount of pegylated interferon-alfa, e.g. , pegylated interferon alfa-2b for a second treatment time period sufficient to eradicate detectable HCV-RNA at least by end of the second treatment time period and to maintain no detectable HCV-RNA for at least 24 weeks after the end of the second treatment time period.

Abstract: A method of reducing cravings in a mammal to food or an addictive substance is disclosed. The method comprises administering to the mammal an effective amount of a D1/D5 antagonist or a D1/D5 partial agonist alone or in combination with other specified CNS compounds.

Abstract: A method of reducing cravings in a mammal to nicotine or tobacco is disclosed. The method comprises administering to the mammal an effective amount of a D1/D5 antagonist or a D1/D5 partial agonist alone or in combination with other specified CNS compounds.